Cargando…

Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results

BACKGROUND: To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC ≥ II. METHODS: 118 patients (median age 64 years; male : female ratio 2.5 : 1) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Guckenberger, Matthias, Wulf, Joern, Thalheimer, Andreas, Wehner, Daniel, Thiede, Arnulf, Müller, Gottfried, Sailer, Marco, Flentje, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806295/
https://www.ncbi.nlm.nih.gov/pubmed/20025752
http://dx.doi.org/10.1186/1748-717X-4-67
_version_ 1782176273172267008
author Guckenberger, Matthias
Wulf, Joern
Thalheimer, Andreas
Wehner, Daniel
Thiede, Arnulf
Müller, Gottfried
Sailer, Marco
Flentje, Michael
author_facet Guckenberger, Matthias
Wulf, Joern
Thalheimer, Andreas
Wehner, Daniel
Thiede, Arnulf
Müller, Gottfried
Sailer, Marco
Flentje, Michael
author_sort Guckenberger, Matthias
collection PubMed
description BACKGROUND: To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC ≥ II. METHODS: 118 patients (median age 64 years; male : female ratio 2.5 : 1) with pathological proven rectal cancer (clinical stage II 50%, III 41.5%, IV 8.5%) were treated preoperatively with twice daily radiotherapy of 2.9 Gy single fraction dose to a total dose of 29 Gy; surgery was performed immediately in the following week with total mesorectal excision (TME). Adjuvant 5-FU based chemotherapy was planned for pathological stage UICC ≥ II. RESULTS: After low anterior resection (70%) and abdominoperineal resection (30%), pathology showed stage UICC I (27.1%), II (25.4%), III (37.3%) and IV (9.3%). Perioperative mortality was 3.4% and perioperative complications were observed in 22.8% of the patients. Adjuvant chemotherapy was given in 75.3% of patients with pathological stage UICC ≥ II. After median follow-up of 46 months, five-year overall survival was 67%, cancer-specific survival 76%, local control 92% and freedom from systemic progression 75%. Late toxicity > grade II was observed in 11% of the patients. CONCLUSIONS: Preoperative short-course radiotherapy, total mesorectal excision and adjuvant chemotherapy for pathological stage UICC ≥ II achieved excellent local control and favorable survival.
format Text
id pubmed-2806295
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28062952010-01-14 Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results Guckenberger, Matthias Wulf, Joern Thalheimer, Andreas Wehner, Daniel Thiede, Arnulf Müller, Gottfried Sailer, Marco Flentje, Michael Radiat Oncol Research BACKGROUND: To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC ≥ II. METHODS: 118 patients (median age 64 years; male : female ratio 2.5 : 1) with pathological proven rectal cancer (clinical stage II 50%, III 41.5%, IV 8.5%) were treated preoperatively with twice daily radiotherapy of 2.9 Gy single fraction dose to a total dose of 29 Gy; surgery was performed immediately in the following week with total mesorectal excision (TME). Adjuvant 5-FU based chemotherapy was planned for pathological stage UICC ≥ II. RESULTS: After low anterior resection (70%) and abdominoperineal resection (30%), pathology showed stage UICC I (27.1%), II (25.4%), III (37.3%) and IV (9.3%). Perioperative mortality was 3.4% and perioperative complications were observed in 22.8% of the patients. Adjuvant chemotherapy was given in 75.3% of patients with pathological stage UICC ≥ II. After median follow-up of 46 months, five-year overall survival was 67%, cancer-specific survival 76%, local control 92% and freedom from systemic progression 75%. Late toxicity > grade II was observed in 11% of the patients. CONCLUSIONS: Preoperative short-course radiotherapy, total mesorectal excision and adjuvant chemotherapy for pathological stage UICC ≥ II achieved excellent local control and favorable survival. BioMed Central 2009-12-21 /pmc/articles/PMC2806295/ /pubmed/20025752 http://dx.doi.org/10.1186/1748-717X-4-67 Text en Copyright ©2009 Guckenberger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Guckenberger, Matthias
Wulf, Joern
Thalheimer, Andreas
Wehner, Daniel
Thiede, Arnulf
Müller, Gottfried
Sailer, Marco
Flentje, Michael
Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
title Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
title_full Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
title_fullStr Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
title_full_unstemmed Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
title_short Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
title_sort prospective phase ii study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 gy to a total dose of 29 gy - long-term results
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806295/
https://www.ncbi.nlm.nih.gov/pubmed/20025752
http://dx.doi.org/10.1186/1748-717X-4-67
work_keys_str_mv AT guckenbergermatthias prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT wulfjoern prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT thalheimerandreas prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT wehnerdaniel prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT thiedearnulf prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT mullergottfried prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT sailermarco prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults
AT flentjemichael prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults